How to Invest in Incyte?
Incyte Investing Guide | INCY |
- Research Incyte's stock before investing in Incyte. It's a good idea to research the company and its stock by analyzing its financial statements, reading news articles, and studying its historical performance, including its growth strategy, change in net worth, competition, and potential risks.
- Choose a brokerage firm to buy shares of Incyte. We recommend well-established brokerages such as Charles Schwab, Fidelity, TD Ameritrade, and Robinhood, but in many ways, it will depend on your individual needs, preferences, and investment goals.
- Open an account at one of the brokerages you have selected. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account. You will need to deposit funds into your brokerage account to purchase Incyte stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order. Once you have located Incyte stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock.
It's important to note that investing in stocks such as Incyte carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions regarding Incyte Stock. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to invest safely in Incyte.
Research Incyte Stock
Researching Incyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E).
About 100.0% of the company shares are owned by institutional investors. The book value of Incyte was currently reported as 23.14. The company has Price/Earnings To Growth (PEG) ratio of 0.69. Incyte had not issued any dividends in recent years. The entity had 2:1 split on the 1st of September 2000. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. To learn more about Incyte call Herve Hoppenot at 302 498 6700 or check out https://www.incyte.com. Other things to consider when investing in Incyte
Another important aspect of Incyte's research is to evaluate the company's potential for future growth. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Incyte's research are outlined below:
| Incyte generated a negative expected return over the last 90 days | |
| Incyte is unlikely to experience financial distress in the next 2 years | |
| Incyte has a strong financial position based on the latest SEC filings | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer |
Incyte Quarterly Cash And Short Term Investments |
|
Check Incyte's earnings reports
Incyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Incyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Use historical earnings surprises to time your Incyte position
Earnings surprises can significantly impact Incyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Incyte's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2015-04-30 | 2015-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
1998-07-14 | 1998-06-30 | 0.09 | 0.1 | 0.01 | 11 | ||
1997-04-17 | 1997-03-31 | 0.03 | 0.02 | -0.01 | 33 | ||
1996-07-25 | 1996-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
2015-08-04 | 2015-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
1999-02-03 | 1998-12-31 | 0.1 | 0.12 | 0.02 | 20 |
Know Incyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Incyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Incyte backward and forwards among themselves. Incyte's institutional investor refers to the entity that pools money to purchase Incyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lsv Asset Management | 2023-12-31 | 2.7 M | Man Group Plc | 2023-12-31 | 2.4 M | Goldman Sachs Group Inc | 2023-12-31 | 2.4 M | Pictet Asset Manangement Sa | 2023-12-31 | 2.3 M | Bellevue Group Ag | 2023-12-31 | 2.2 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 2.1 M | Northern Trust Corp | 2023-12-31 | 2 M | Norges Bank | 2023-12-31 | 2 M | Legal & General Group Plc | 2023-12-31 | 2 M | Baker Bros Advisors Lp | 2023-12-31 | 36.2 M | Blackrock Inc | 2023-12-31 | 24.3 M |
Follow Incyte's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.66 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte's market, we take the total number of its shares issued and multiply it by Incyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Evaluate Incyte's profitablity
Incyte's profitability indicators refer to fundamental financial ratios that showcase Incyte's ability to generate income relative to its revenue or operating costs. If, let's say, Incyte is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Incyte's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Incyte's profitability requires more research than a typical breakdown of Incyte's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.1 | |
| Return On Capital Employed | 0.11 | 0.12 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.12 | 0.19 |
Determining Incyte's profitability involves analyzing its financial statements and using various financial metrics to assess its ability to generate profits. Also, when deciding whether to invest in Incyte, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Incyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Incyte's profitability and make more informed investment decisions.
The data published in Incyte's official financial statements usually reflect Incyte's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Incyte. For example, before you start analyzing numbers published by Incyte accountants, it's critical to develop an understanding of what Incyte's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Incyte's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Please utilize our Beneish M Score to check the likelihood of Incyte's management manipulating its earnings.
Evaluate Incyte's management efficiency
Incyte has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 23.21 | 24.37 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 21.96 | 23.06 | |
| Enterprise Value Over EBITDA | 12.01 | 12.61 | |
| Price Book Value Ratio | 2.71 | 2.84 | |
| Enterprise Value Multiple | 12.01 | 12.61 | |
| Price Fair Value | 2.71 | 2.84 | |
| Enterprise Value | 12.7 B | 13.4 B |
The analysis of Incyte's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Incyte's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Incyte Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.672 |
Basic technical analysis of Incyte Stock
As of the 24th of April, Incyte retains the Market Risk Adjusted Performance of (0.77), risk adjusted performance of (0.11), and Standard Deviation of 1.3. Incyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down thirteen technical drivers for Incyte, which can be compared to its competitors. Please check out Incyte market risk adjusted performance and treynor ratio to decide if Incyte is priced fairly, providing market reflects its last-minute price of 51.65 per share. Given that Incyte has information ratio of (0.25), we strongly advise you to confirm Incyte's regular market performance to make sure the company can sustain itself at a future point.Check Incyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Baker Bros. Advisors Lp over three weeks ago Acquisition by Baker Bros. Advisors Lp of 543 shares of Incyte subject to Rule 16b-3 | ||
Whitfield Roy A over a year ago Sale by Whitfield Roy A of 30000 shares of Incyte |
Incyte's technical indicators
Using predictive indicators to make investment decisions involves analyzing Incyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.77) | |||
| Mean Deviation | 1.0 | |||
| Coefficient Of Variation | (542.08) | |||
| Standard Deviation | 1.3 | |||
| Variance | 1.69 | |||
| Information Ratio | (0.25) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.78) | |||
| Maximum Drawdown | 6.54 | |||
| Value At Risk | (2.40) | |||
| Potential Upside | 1.87 | |||
| Skewness | 0.0209 | |||
| Kurtosis | 0.2673 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.77) | |||
| Mean Deviation | 1.0 | |||
| Coefficient Of Variation | (542.08) | |||
| Standard Deviation | 1.3 | |||
| Variance | 1.69 | |||
| Information Ratio | (0.25) | |||
| Jensen Alpha | (0.28) | |||
| Total Risk Alpha | (0.42) | |||
| Treynor Ratio | (0.78) | |||
| Maximum Drawdown | 6.54 | |||
| Value At Risk | (2.40) | |||
| Potential Upside | 1.87 | |||
| Skewness | 0.0209 | |||
| Kurtosis | 0.2673 |
Consider Incyte's intraday indicators
Incyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Incyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 39635.22 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 51.81 | |||
| Day Typical Price | 51.75 | |||
| Price Action Indicator | (0.29) | |||
| Period Momentum Indicator | (0.27) | |||
| Relative Strength Index | 36.14 |
Incyte Corporate Filings
F4 | 2nd of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 27th of March 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 25th of March 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 13th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Choose a brokerage platform to buy Incyte's shares
In investing, finding the right broker is a crucial step for anyone looking to embark on a journey into the stock market. It all begins with a thorough comparison of costs and fees, as low-cost or commission-free brokers can significantly impact an investor's returns. However, the cheapest option is not always the best choice. The adventure continues with exploring various trading platforms, seeking one that is user-friendly, reliable, and functional. The ideal platform will provide the necessary research, analysis, and investment monitoring tools. As the quest goes on, it's essential to consider the different account types brokers offer, such as individual, joint, and retirement accounts. In addition, for those interested in trading on margin, brokers offering margin accounts should also be considered. The journey leads to the discovery of brokers that provide a wide range of investment options, including stocks, bonds, ETFs, and mutual funds. This diversity allows investors to build well-rounded portfolios that suit their needs and goals. Customer service is another crucial factor in this decision-making process. The perfect broker would have a responsive, knowledgeable, and available customer support team ready to assist with various issues or investment decisions. Aspiring investors should seek brokers with quality research, market analysis, and educational resources. These tools are essential for making informed decisions and improving investment knowledge. It's also vital to ensure that the broker is regulated by an appropriate regulatory body and has robust security measures to protect personal and financial information. Additionally, account minimums and funding options should be taken into consideration. A broker with flexible account minimums and various funding options, such as wire transfers, ACH transfers, or check deposits, will cater to different investor needs. A seamless mobile and web experience is a must in today's fast-paced world. The ideal broker will allow investors to manage their investments easily on the go. Finally, it is essential to consider various brokers' reviews and conduct reputation analysis. By reading online assessments and seeking recommendations, valuable insights into each broker's reputation can be gathered. After a thorough investigation, you can find a broker that checks all the boxes and aligns with their preferences and requirements regarding taking a position in Incyte.
Open brokerage account to buy Incyte Stock
Once you've selected a broker, visit their website or a local branch to initiate the account-opening process. Most brokers offer online account opening, which is typically faster and more convenient. When you begin the process, you'll need to select the type of account you want to open. This may include individual, joint, or retirement accounts. Some brokers may also offer margin accounts, which allow you to trade on margin. Next, you'll need to complete the application form. Whether you're filling out an online or paper application, you'll need to provide personal information, such as your name, address, Social Security Number or other tax identification number, date of birth, and employment information. You may also be asked about your investment experience, financial situation, and goals. After completing the application form, review it carefully for accuracy and submit it to the broker. Some brokers may require you to provide additional documentation, such as a copy of your driver's license or passport, for identity verification. Once your application is submitted, the broker will review it and may run a background check or verify your credit history. You'll receive an email or notification with your new brokerage account details if your application is approved.
Fund your account to invest in Incyte Stock
Once your account is open, you can fund it by linking your bank account to your brokerage account. To do this, log in to your brokerage account and look for an option to add or link a bank account. You will need to provide your bank account number and the routing number for your bank. This information can be found on your checks or by contacting your bank. After linking your bank account, you can initiate a transfer of funds from your bank account to your brokerage account. This process may vary depending on the brokerage, but generally, you will need to navigate to the funding or deposit section of the brokerage website or app. From there, you can choose the linked bank account and enter the amount you wish to transfer. Keep in mind that there may be limits on the amount you can transfer in a single transaction, and the transfer may take several business days to complete. Some brokerages also offer other funding options, such as wire transfers, mailing a check, or transferring assets from another brokerage. If you prefer to use one of these methods, check with your brokerage firm for specific instructions. Once the funds are in your brokerage account, you can use them to purchase investments such as stocks, bonds, mutual funds, or other financial instruments.
Place your Incyte Stock order
Placing an Incyte purchase order involves providing instructions to your selected brokerage firm to aquare shares of Incyte on your behalf. First, your will need to access your brokerage account through their website or mobile app using your login credentials. Make sure you have sufficient funds in your account to cover the cost of the stock purchase, including any applicable fees or commissions. Once you are logged in, locate the trading platform or order entry section within the brokerage interface. It may be labeled as "Trade," "Order Entry," or something similar. Next, you will need to provide the necessary information to place your stock order. This typically includes: .
After entering the necessary information, review your order carefully to ensure it reflects your intentions accurately. When you are ready, submit your order by clicking the "Submit," "Place Order," or equivalent button. Your brokerage firm will then execute your order according to your instructions, subject to market conditions and the availability of shares. Keep in mind that market orders may be executed immediately, while limit orders, stop orders, and stop-limit orders will only be executed if the specified conditions are met. Finally, monitor your order status and confirm its execution. You can usually find this information in the "Order History" or "Order Status" section of your brokerage account.
| Ticker | Enter the ticker symbol, which is the unique series of letters representing the stock, e.g., INCY for Incyte | |
| Type | Choose the type of order you want to place. The most common order types are market orders, limit orders, stop orders, and stop-limit orders. Each order type has its own advantages and drawbacks, so be sure to research and understand them before placing your order. | |
| Quantity | Specify the number of shares you want to buy or sell | |
| Duration | Indicate the duration for which your order will be active. You can choose from options like "Day" (valid only for the current trading day) or "Good 'til Canceled" (valid until you manually cancel the order) |
Monitor your Incyte Stock position
Monitoring your stock positions with your brokerage involves regularly checking the status and performance of your investments. Here's how you can monitor your stock positions using your brokerage account: First, access your account by signing in to your brokerage firm's website or mobile app using your login credentials. Once you're logged in, look for the section that displays your account information and portfolio holdings. This section may be labeled as "Portfolio," "Positions," "Holdings," or something similar. In this section, you'll generally find a list of the stocks and other investments that you own, along with relevant details such as the number of shares, the current market value, and the percentage change in value since the last trading day's close. You might also see the total cost of your investment, your current profit or loss, and the percentage gain or loss. Many brokerages also provide tools and features that allow you to analyze and track your stock positions more effectively. These may include:
As you continue to monitor your Incyte Stock position, remember that in order to be an effective trader, it is critical to understand your entire portfolio's sensitivity to market volatility and how your single Incyte position affects your overall exposure to market risk. One of the techniques to manage your overall risk is pair trading, a market-neutral trading strategy enabling traders to profit from virtually any market condition, whether it is experiencing an uptrend or downtrend movement.
| Performance Charts | These charts visually represent the historical price movement of your stocks over different time frames. You can use them to assess the trends and volatility of your investments. | |
| Stock Alerts | You can set up custom alerts to receive notifications when a stock reaches a certain price, percentage change, or other criteria. This can help you stay informed about significant market movements affecting your investments. | |
| Watchlists | Create watchlists to track the performance of stocks you are interested in but have not yet purchased. This can help you identify potential opportunities or risks. | |
| Research Tools | Brokerages often provide access to research tools, such as stock screeners, analyst reports, and financial statements, to help you make more informed investment decisions. |
Moving together with Incyte Stock
| 0.9 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.65 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
| 0.65 | GNTA | Genenta Science SpA Downward Rally | PairCorr |
Moving against Incyte Stock
| 0.63 | ELYM | Eliem Therapeutics | PairCorr |
| 0.56 | OPT | Opthea | PairCorr |
| 0.54 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.46 | MRK | Merck Company Earnings Call Tomorrow | PairCorr |
| 0.46 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.46 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Incyte Stock across various news and media outlets
Far too much social signal, news, headlines, and media speculation about Incyte that are available to investors today. That information is available publicly through Incyte media outlets and privately through word of mouth or via Incyte internal channels. However, regardless of the origin, that massive amount of Incyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Incyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Incyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Incyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Incyte alpha.